Emergent BioSolutions Inc. (EBS) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Emergent BioSolutions Inc. (EBS) closed at USD 6.91 on 2026-10-14, a change of -27 % over the past year, with a market capitalization of USD 368.14M.

Emergent BioSolutions Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Emergent BioSolutions Inc. key figures

Previous close

USD 6.91 (2026-10-14)

1-year change

-27 %

Market cap

USD 368.14M

Enterprise value

USD 816.64M

P/E ratio (trailing)

-2.11

P/E ratio (forward)

6.86

EPS (trailing)

-3.40

EPS (forward)

1.05

PEG ratio

0.38

Price to book

1.08

Revenue growth

66.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.24

Employees

900

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Emergent BioSolutions Inc. and compare it with other stocks.